Which Googlers are Top Writers 2015

Drug Ordinance Report 2017 pp 181-194 | Cite as

  • Jana Bauckmann
  • Ulrich Laitenberger
  • Melanie Schröder
  • Carsten Telschow
  • 2Citations
  • 1.8kDownloads

Summary

In the discussions on drug supply for the last 15 years, both health insurances and manufacturers have increasingly proposed competitive models (Glaeske et al. 2003, Wasem et al. 2005, Cassel and Wille 2006, Klauber and Schleert 2006, Wille et al. 2008, Nink and Schröder 2009). Since 2003, the health insurance companies have been able to conclude insurance-specific discount agreements with manufacturers in Section 130a, Paragraph 8 of the Book V of the Social Code.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

literature

  1. Baars C (2016): Dealing with drug residues. Too big packs - the rest will be burned. http://www.tagesschau.de/inland/arznei-recherche-101.html, Tagesschau. de (07/25/2017)
  2. Bauer C, Hunold M, Hüschelrath K, Jahn R, Kotschedoff M, Laitenberger U, Lux G, May UM, Walendzik A, Wasem J, Weegen L (2015): Discount contract tenders in the generics industry in Germany - effects on market structure, provider diversity and competition . Nomos, Baden-BadenGoogle Scholar
  3. Bretthauer B (2014): Biosimilars 2.0. Setting the course for sustainable supply. IMPLICONplus 06Google Scholar
  4. Cassel D, Wille E (2006): Market and competition theory analysis of the regulation of the SHI pharmaceutical market. Part 3 of the report: Controlling drug spending and strengthening the research location for the pharmaceutical industry. http://wido.de/fileadmin/wido/downloads/pdf_arzneimittel/wido_arz_gutachten_bmg_0806.pdf (May 31, 2017)
  5. Deutsche Apothekerzeitung (2016): AOK BW vs PRO Generika - "The effect is decisive, not the quota". https://www.deutsche-apotheker-zeitung.de/news/artikel/2016/01/06/die-ffekt-entscheidet-nicht-die-quote (May 30, 2017)
  6. Diessel C, Focke K (2015): New Medicines: Central Reimbursement Amount Negotiations versus Decentralized Contract Conclusions. G&S Health and Social Policy 69 (3–4): 74–78Google Scholar
  7. National Association of Statutory Health Insurance Funds (2015): 10 fields of action for the quality and financial viability of drug supply Position paper of the National Association of Statutory Health Insurance Funds. https://www.gkv-spitzenverband.de//media/dokumente/presse/publikationen/Positionspapier_Arzneimittel_barrierefrei.pdf (May 30, 2017)
  8. Glaeske G, Klauber J, C.H.R. L, Selke GW (2003): Strengthening competition in drug supply to increase consumer benefit, efficiency and quality. Expert opinion on behalf of the Federal Ministry for Health and Social Security (BMGS). https://publikationsserver.tu-braunschweig.de/servlets/MCRFileNode-Servlet/digibib_derivate_00002336/wido_arz_gut-bmgslg_0403.pdf (01.06.2017)
  9. Heltweg B, Fetzer S, Wolf T (2010): From portfolio to active ingredient contracts - Are aspects of adequate supply taken into account? Monitor Health Services Research 3 (3): 46–50Google Scholar
  10. Hermann C, Wienands F (2010): Pharmaceutical discount contracts: development, benefits and supply aspects of a successful model. Monitor Health Services Research 3 (3): 29–33Google Scholar
  11. IMS Health (2015): Best Practice Approaches for Drug Bottlenecks in International Comparison. Expert opinion on measures in the event of drug shortages in Germany, the USA, Canada and selected European countries (with a focus on generics) http://www.progenerika.de/wp-content/uploads/2015/03/ProGenerika_IMS-Gutachten-Lieferengp%C3% A4sse-final.pdf. (05/31/2017)
  12. Kaesbach W (2008): Pharmaceutical market: End of discount agreements? What are reasonable alternatives? Presentation at the German Generics Association on May 5, 2008 in Berlin, presented at the conference: German Generics Association in Berlin, August 5, 2008Google Scholar
  13. Klauber J, Schleert N (2006): More courage to compete. Health and Society 9 (4): 32–39Google Scholar
  14. Laitenberger U (2017): Drug Procurement Auctions and Supply Uncertainty. ZEW Discussion Papers. Upcoming Google Scholar
  15. Lexchin J, Bero L, Djulbegovic B, Clark O (2003): Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326 (7400): 1167-1170Google Scholar
  16. Morgan S, Daw J, Thomson P (2013): International best practices for negotiating ‘reimbursement contracts’ with price rebates from pharmaceutical companies. Health Affairs 32 (4): 771-777 Google Scholar
  17. Morton FM (1999): Entry decisions in the generic pharmaceutical industry. The Rand journal of economics 30 (3): 421-440Google Scholar
  18. Nink K, Schröder H (2009): Medicines in competition. Health and Society 12 (9): 35–41Google Scholar
  19. Expert council for assessing developments in the health care system (2012): Competition at the interface between outpatient and inpatient health care. http://www.svr-gesundheit.de/fileadmin/user_upload/Gutachten/2012/GA2012_Langfassung.pdf (01.06.2017)
  20. Expert Council for the Assessment of Developments in the Health Care System (2014): Needs-based care - Perspectives for rural regions and selected service areas. http://www.svr-gesundheit.de/fileadmin/user_upload/Aktuelles/2014/SVR-Gutachten_2014_Kurzfassung_01.pdf (01.06.2017)
  21. Schellhorn H, Zerwes U, Rosery H (2013): Budget Impact in the Early Benefit Assessment. Health Economics & Quality Management 18 (04): 180–185Google Scholar
  22. Schröder H, Telschow C, Schaufler J (2014): Impact of discount contract tenders. Monitor Health Services Research 7 (4): 31–37Google Scholar
  23. Sträter B (2014): Discount agreements and competition. Pharm Ind 76 (6): 837-838 Google Scholar
  24. Tebroke E (2017): Obligation to report the bottleneck. Pharmaceutical Newspaper 2017 (11) Google Scholar
  25. Association of researching pharmaceutical manufacturers (2015): vfa position paper “Research and Biotech Location Germany”. https://www.vfa.de/embed/pos-forschungs-und-biotech-standort-deutschland.pdf (May 31, 2017)
  26. Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, Pedersen HB, Dedet G, Babar Z (2017): How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. Applied health economics and health policy 15 (3): 307-321 Google Scholar
  27. Wasem J, Greß S, Niebuhr D (2005): Regulation of the market for prescription drugs in an international comparison. Expert opinion on behalf of the BAH. https://www.aerzteblatt.de/download/files/2005/03/x0000114394.pdf (01.06.2017)
  28. Wieseler B, Wolfram N, McGauran N, Kerekes M, Vervölgyi V, Kohlenpp P, Kamphuis M, Grouven U (2013): Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS medicine 10 (10) Google Scholar
  29. Wille E, Cassel D, Ulrich V (2008): Further development of the health system and the pharmaceutical market. Report for the Association of Research-Based Pharmaceutical Manufacturers e.V. Berlin. https://www.vfa.de/download/gutachten-wille-cassel-ulrich.pdf (01.06.2017)

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Jana BauckmannEmail author
  • Ulrich Laitenberger
  • Melanie Schröder
  • Carsten Telschow
  1. 1. Scientific Institute of the AOK (WIdO) Berlin, Germany
  2. 2. Department of Sciences économiques et socialesTélécom ParisTechParisFrance
  3. 3rd Scientific Institute of AOKBerlinGermany